Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Putin visits Harbin Institute of TechnologyVindicated by Supreme Court, CFPB director says bureau will add staff, consider new rules on banksChinese vice premier visits Uzbekistan, coEU probes Facebook, Instagram over child safetyTyson Fury meets Oleksandr Usyk for the undisputed heavyweight title in Saudi ArabiaTexas Gov. Greg Abbott gave few pardons before rushing to clear Army officer who killed a protesterPutin proposes reappointing Mishustin as Russian PM: mediaPeng Liyuan visits HungarianChinese FM holds talks with Tanzanian counterpartChina, Kazakhstan pledge to deepen pragmatic cooperation
2.8591s , 6496.0546875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,World Wonders news portal